Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M07D1 vs Chemotherapy in HER2-Expressing Platinum-Resistant Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
NCT07545460Phase 3Not yet recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Jul 2026
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of BL-M07D1 in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Biokin Pharmaceutical. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
BL-M07D1
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT07545460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07545460.